If patient has rhd how to decide whether patient is ideal to start on acitrome

Reading File
Finding Sources
Finding Sources
Searching the Web

Acitrom acenocoumarol indications RHD rheumatic heart disease criteria for starting anticoagulation

Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
I now have sufficient information to give a comprehensive, well-structured answer.

Deciding Whether to Start Acitrom (Acenocoumarol) in RHD

Acitrom is an oral vitamin K antagonist (VKA) - the same class as warfarin - and in the Indian context it is the most commonly used VKA for long-term anticoagulation in RHD. The decision to start involves three steps: establishing the indication, ruling out contraindications, and confirming the patient is suitable for INR monitoring.

Step 1: Confirm a Clear Indication

Acitrom is indicated in RHD patients in the following situations:
IndicationINR Target
Mitral stenosis + Atrial fibrillation (paroxysmal, persistent, or permanent)2.5 - 3.5
Mitral stenosis + Prior systemic embolism (even in sinus rhythm)2.5 - 3.5
Mitral stenosis + Left atrial thrombus on echo2.5 - 3.5
Mechanical prosthetic valve (post-surgical replacement)2.5 - 3.5 (mitral); 2.0 - 3.0 (aortic)
Mitral stenosis in sinus rhythm with left atrial diameter >55 mm or spontaneous echo contrast2.0 - 3.0 (Class IIa, reasonable)
Key point from Goldman-Cecil Medicine: "Because patients with concomitant mitral stenosis and atrial fibrillation have an extraordinarily high risk for systemic embolism, they should undergo chronic anticoagulation with warfarin at an INR target of 2.5 to 3.5 unless there is a serious contraindication... Atrial fibrillation with rheumatic mitral stenosis or a mechanical heart valve requires VKA anticoagulation instead of direct-acting oral anticoagulants (DOACs)." - Goldman-Cecil Medicine
DOACs (rivaroxaban, apixaban, dabigatran) are NOT acceptable substitutes for rheumatic AF or mechanical valves - VKA (Acitrom/warfarin) is mandatory in these scenarios.

Step 2: Assess Contraindications (When NOT to Start)

Absolute contraindications:
  • Active bleeding (GI, intracranial, etc.)
  • Recent hemorrhagic stroke or intracranial bleed
  • Pregnancy (especially first trimester and near term - fetal warfarin syndrome risk)
  • Severe thrombocytopenia (platelets <50,000)
  • Known bleeding disorders (hemophilia, severe liver failure with coagulopathy)
Relative contraindications (weigh risk vs. benefit):
  • Recent major surgery or trauma
  • Uncontrolled hypertension (BP >180/110 mmHg)
  • Active peptic ulcer disease
  • Heavy alcohol use or poor compliance
  • Inability to monitor INR (no access to lab)
  • Falls risk in elderly

Step 3: Confirm Patient Suitability (Practical Checklist)

Before starting Acitrom, assess:
  1. Indication confirmed - AF, prior embolism, mechanical valve, large LA with spontaneous echo contrast?
  2. Baseline investigations done - CBC, liver function tests, renal function, baseline INR/PT, baseline ECG and echo
  3. INR monitoring is feasible - Patient lives near a lab, can come for regular INR checks (initially weekly until stable, then monthly)
  4. Interacting drugs identified - Many drugs alter Acitrom metabolism (NSAIDs increase bleeding risk; antibiotics, antifungals, amiodarone potentiate it; rifampicin reduces it)
  5. Dietary consistency - Patient counselled about consistent vitamin K intake (green leafy vegetables affect INR)
  6. Patient counselled about bleeding signs and when to seek emergency care
  7. No active bleeding source (check for history of GI bleed, haematuria, epistaxis)

Important Note: RHD in Sinus Rhythm Without AF

  • Mild-to-moderate mitral stenosis in sinus rhythm without prior embolism or LA thrombus - Acitrom is generally NOT routinely indicated
  • Anticoagulation in this scenario remains controversial and is individualized based on echo findings (LA size, spontaneous contrast)

Summary Decision Algorithm

RHD Patient
    |
    ├─ Has AF / Prior embolism / Mechanical valve?
    │       YES → Acitrom INDICATED (mandatory VKA, not DOAC)
    │
    ├─ Sinus rhythm + Large LA (>55mm) or spontaneous echo contrast?
    │       YES → Acitrom REASONABLE (Class IIa)
    │
    ├─ Sinus rhythm + No above risk factors?
    │       → Acitrom NOT routinely indicated
    |
    └─ Any indication present?
            Check contraindications → If none, confirm INR monitoring feasibility → Start Acitrom
Starting dose of Acitrom: Typically 2-4 mg/day, adjusted based on INR response. INR is checked after 3-4 days of initiation, then weekly until 2 consecutive therapeutic readings, then monthly. The therapeutic range is 2.0-3.0 for most indications and 2.5-3.5 for mitral stenosis with AF or mechanical mitral valves.

Patient have suspected tbm

Reading File
Asking for Preferences
Finding Sources
Searching the Web

tuberculous meningitis diagnosis treatment guidelines 2024 CSF criteria ATT steroids

Reading File
Reading File
Reading Web Page

https://emedicine.medscape.com/article/1166190-treatment

Reading File
Finding Sources
Reading File
Reading File
Loading Image
Here is a complete clinical guide to suspected TBM.

Tuberculous Meningitis (TBM) - Complete Clinical Guide


1. Clinical Presentation

TBM characteristically has a subacute onset over 1-2 weeks - slower than typical bacterial meningitis. Key features:
Classical symptoms:
  • Headache (>50% of cases), low-grade fever, malaise, anorexia for days to weeks
  • Neck rigidity / meningism (75% of cases), Kernig's and Brudzinski's signs
  • Lethargy, confusion, altered sensorium
Features that point specifically toward TBM:
  • Cranial nerve palsies - especially ocular (CN III, IV, VI) due to basal exudate (20% of cases)
  • Symptoms >5 days before presentation
  • History of TB exposure or contact, prior TB, or immunocompromise (HIV)
  • Evidence of TB elsewhere - pulmonary TB on CXR in ~2/3 of cases
  • Systemic TB features: weight loss, night sweats, prolonged cough >2 weeks
Risk factors: HIV, malnutrition, diabetes, steroid use, young children, immigrants from high-burden countries.

2. Diagnosis

Uniform Case Scoring System (Marais Criteria)

Use this scoring system to classify TBM before confirmatory results:
CategoryFeaturePoints
Clinical (max 6)Symptom duration >5 days4
Systemic TB symptoms (weight loss, night sweats, cough >2 wk)2
TB contact / positive TST/IGRA (child <10 yr)2
Focal neurological deficit (excluding CN palsy)1
Cranial nerve palsy1
Altered consciousness1
CSF (max 4)Clear appearance1
Cells 10-500/μL1
Lymphocyte predominance >50%1
Protein >1 g/L1
CSF:plasma glucose <50% or CSF glucose <2.2 mmol/L1
Neuroimaging (max 6)Hydrocephalus1
Basal meningeal enhancement2
Tuberculoma2
Infarct1
Pre-contrast basal hyperdensity (CT)2
TB elsewhere (max 4)CXR - active TB (non-miliary)2
CXR - miliary TB4
CT/MRI/US evidence of extracranial TB2
Classification:
  • Definite TBM: AFB on CSF smear, positive CSF culture, or positive Xpert MTB/RIF + suggestive clinical features
  • Probable TBM: Score ≥12 (if neuroimaging available) or ≥10 (if no neuroimaging). At least 2 points must come from CSF or imaging criteria
  • Possible TBM: Score 6-11 (imaging available) or 6-9 (no imaging); alternative diagnosis not confirmed

CSF Analysis (Lumbar Puncture - cornerstone of diagnosis)

ParameterTypical TBM Finding
Opening pressureRaised (often >200 mm H₂O)
AppearanceClear / slightly turbid / xanthochromic
White cells10-1000/μL, lymphocyte predominance (early = neutrophils)
ProteinElevated: 1-8 g/L (100-800 mg/dL)
GlucoseLow (<45 mg/dL); CSF:blood glucose <50%
AFB smearPositive in only 10-40% (low sensitivity); do at least 3 samples
CultureGold standard - positive in up to 80%; takes 4-8 weeks
Xpert MTB/RIFSensitivity ~80%, specificity high - preferred first test
ADA (adenosine deaminase)Elevated (>10 U/L supportive)
Harrison's 22e: "AFBs are infrequently seen on direct smear of CSF sediment, but repeated lumbar punctures increase the yield. Culture is diagnostic in up to 80% and remains the gold standard. Xpert MTB/RIF has sensitivity up to 80% and is the preferred initial option. A negative result does NOT exclude TBM."
Important: Do NOT delay ATT for culture results. Treat empirically if clinical suspicion is high.

Neuroimaging

MRI with gadolinium is preferred over CT. Classic findings:
MRI TBM - gadolinium enhancement of basal meninges with hydrocephalus
MRI in TBM: Gadolinium enhancement of the basal meninges (bright white areas at the base of brain), multiple abscesses, and hydrocephalus - from Adams & Victor's Principles of Neurology
  • Basal meningeal enhancement (most characteristic)
  • Hydrocephalus (communicating, due to obstruction of basal cisterns)
  • Infarcts (from vasculitis of perforating arteries)
  • Tuberculomas (ring-enhancing lesions)

Other Investigations

  • CXR - look for pulmonary TB, miliary pattern
  • Mantoux / TST - helpful if positive, but negative in immunocompromised
  • IGRA (Interferon-gamma release assay) - QuantiFERON
  • Sputum AFB / GeneXpert if pulmonary involvement suspected
  • HIV serology - mandatory in all TBM cases
  • Blood: CBC, LFT, RFT, electrolytes (hyponatremia from SIADH is common)
  • Fundoscopy - papilledema, choroidal tubercles

3. Treatment

ATT Regimen

PhaseDurationDrugsNotes
Intensive2 monthsHRZE (INH + Rifampicin + Pyrazinamide + Ethambutol)Four-drug regimen
Continuation7-10 monthsHR (INH + Rifampicin)Total duration 9-12 months for TBM
Total duration: 9-12 months (longer than pulmonary TB due to CNS penetration issues)
Drug doses (adults):
  • Isoniazid (H/INH): 5 mg/kg/day (max 300 mg) - best CNS penetration
  • Rifampicin (R/RIF): 10 mg/kg/day (max 600 mg)
  • Pyrazinamide (Z/PZA): 20-35 mg/kg/day
  • Ethambutol (E/EMB): 15 mg/kg/day
Note: Ethambutol and ethionamide have poor CSF penetration once inflammation resolves. Fluoroquinolones (levofloxacin/moxifloxacin) have excellent CNS penetration and are useful in MDR-TBM as fourth drugs.
Add pyridoxine 50 mg/day with INH to prevent peripheral neuropathy.

Adjunctive Corticosteroids (MANDATORY)

Corticosteroids reduce mortality and should be given in all TBM patients (except special circumstances).
Dexamethasone regimen (WHO/guidelines):
WeeksRouteDose
Week 1IV0.4 mg/kg/day
Week 2IV0.3 mg/kg/day
Week 3IV0.2 mg/kg/day
Week 4IV0.1 mg/kg/day
Weeks 5-6Oral4 mg/day, then taper by 1 mg/week
Total steroid duration: 6-8 weeks with tapering.
Harrison's 22e: "Clinical trials demonstrated that patients given adjunctive glucocorticoids experience faster resolution of CSF abnormalities and elevated CSF pressure, resulting in lower rates of death or severe disability and relapse. Dexamethasone significantly enhanced survival among persons >14 years."
Note on HIV patients: A recent placebo-controlled trial showed no benefit from adjunctive dexamethasone in TBM patients with HIV - individualise this decision.
Alternatively, prednisolone 60 mg/day orally, tapered over 6-8 weeks, is acceptable.

4. Complications and Monitoring

Common Complications

ComplicationMechanismManagement
HydrocephalusBasal exudate blocking CSF flowSerial LPs; VP shunt or EVD if progressive
Stroke / InfarctVasculitis of perforating arteriesSupportive; optimise ATT
HyponatremiaSIADH (very common)Fluid restriction, hypertonic saline if severe
SeizuresCortical irritation, infarct, TBAEDs; levetiracetam or phenytoin
Cranial nerve palsiesBasal exudateUsually improve with treatment
Raised ICPHydrocephalusMannitol, dexamethasone, LP, shunt
ArachnoiditisChronic inflammationSteroids, hyaluronidase intrathecally in some cases
Note on VP shunting: Required in up to 25% of cases with obstructive hydrocephalus. Shunt complications (infection, malfunction) occur in 20-40% of cases.

Monitoring During Treatment

  1. Serial LPs - monitor CSF cell count, protein, glucose response
  2. Serial neuroimaging (especially if tuberculoma present - may initially enlarge before resolving)
  3. LFTs monthly - INH and RIF are hepatotoxic; stop ATT if symptomatic hepatitis or ALT >3x ULN with symptoms
  4. Visual acuity and color vision - Ethambutol can cause optic neuropathy (check monthly)
  5. Serum sodium - watch for SIADH
  6. GCS / neurological status - daily in acute phase
  7. Uric acid - Pyrazinamide causes hyperuricemia

5. Prognosis

  • Overall mortality: ~10-20% in treated cases; up to ~50% when treatment is delayed to the coma stage
  • Neurological sequelae in 20-30% of survivors: cognitive impairment, seizures, hemiparesis, visual defects, deafness
  • HIV co-infection worsens prognosis significantly (mortality ~21% or higher)
  • Key message: Early diagnosis and immediate ATT initiation is the single most important determinant of outcome

Summary - Immediate Action in Suspected TBM

Suspected TBM
    ↓
1. Urgent CT/MRI head (rule out mass lesion before LP)
2. Lumbar puncture → CSF for: cells, protein, glucose, AFB smear, culture, Xpert MTB/RIF, ADA
3. CXR, HIV test, LFT, RFT, electrolytes, CBC
4. Start ATT IMMEDIATELY (do not wait for culture)
    → 2HRZE / 7-10HR
5. Add Dexamethasone (taper over 6-8 weeks)
6. Pyridoxine 50mg/day with INH
7. Monitor for hyponatremia, raised ICP, seizures
8. Neurosurgery consult if hydrocephalus develops
(Sources: Harrison's Principles of Internal Medicine 22e, Adams & Victor's Principles of Neurology 12e, Marais Uniform Case Definition Criteria, Index-TB Guidelines India, Medscape TBM Guidelines)
This is a shared conversation. Sign in to Orris to start your own chat.